Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine

The number of participants achieving a Partial Response (PR) or Complete Response (CR) at the end of therapy as measured via PET/CT response. Response is evaluated using the Revised International Working Group Criteria.

• CR: Disappearance of all evidence of disease
• PR: Regression of measurable disease and no new sites

A summary of the grade 3 or 4 adverse events experienced by participants as determined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The data is shown as the number of participants that experienced at least one grade 3 or 4 adverse event for each of the specified toxicities.

Lugano Classification of disease stage

• Stage I: Found in only 1 lymph node or lymphoid organ or the cancer is found in only 1 area of a single organ outside the lymph system.
• Stage II: The cancer is found in 2 or more lymph node areas on the same side of the diaphragm or the cancer extends locally from one lymph node area into a nearby organ

Can be assigned a letter A or B. B is when a patient has any of the following symptoms:

• Loss of > than 10% of body weight over the previous 6 months without dieting
• Unexplained fever of at least 100.4°F (38°C)
• Drenching night sweats

Hypercellular indicates more cells are being produce than expected, hypocellular means that fewer than expect number of cells are being produced, normocellular means an approximately normal amount of cells are being produced

The histological subtypes of classic Hodgkin lymphoma:

• Classical NOS: Not Otherwise Specified (specific subtype not identified)
• Lymphocyte-Rich: Rarely found in more than a few lymph nodes and usually occurs in the upper half of the body
• Mixed Cellularity: Seen predominantly in adults, this is the second most common type. It can start in any lymph node but most often occurs in the upper half of the body.
• Nodular Sclerosis: The most common type in developed countries. This most common in teens and young adults. Tends to start in lymph nodes in the chest or neck.

Early Unfavorable: Stage I or II disease and one or more of the following risk factors:

• B Symptoms (see stage description)
• Extranodal disease
• Bulky disease (≥10 cm or >33% of the chest diameter on chest x-ray)
• Three or more sites of nodal involvement
• Sedimentation rate of ≥50 mm/h

Early Favorable: Stage I or II disease with none of the risk factors listed above. Patients with favorable classification tend to have better outcomes.

Information is missing for one participant

Information is missing for one participant

The number of participants achieving a Partial Response (PR) or Complete Response (CR) after one cycle of Brentuximab monotherapy as measured via PET/CT response. Response is evaluated using the Revised International Working Group Criteria.

• CR: Disappearance of all evidence of disease
• PR: Regression of measurable disease and no new sites

The number of participants achieving a Partial Response (PR) or Complete Response (CR) at the end of therapy as measured via PET/CT response. Response is evaluated using the Revised International Working Group Criteria.

• CR: Disappearance of all evidence of disease
• PR: Regression of measurable disease and no new sites

Two participants were not evaluated for response due to a death and a withdrawal.

A summary of the grade 3 or 4 adverse events experienced by participants as determined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The data is shown as the number of participants that experienced at least one grade 3 or 4 adverse event for each of the specified toxicities.